Goldman Sachs Initiates Immunome Coverage: Buy Rating

Goldman Sachs gave Immunome a "Buy" rating ($26 target). The company creates potentially best-in-class cancer drugs, including Varegacestat, which is seen as "differentiated." Key trial results are expected at the end of 2025.